Clinical Spotlight
65-year-old male with FEV₁ improvement from
24% to 31% with Zephyr Valves
| Patient Profile | |
|---|---|
| Quality of Life Goal | Be able to breathe without struggling and move around without difficulty |
| Condition |
|
| Smoking History |
|
| Management Medications |
|
| Oxygen Use |
|
| Baseline FEV1 |
|
| Symptoms |
|
| Special Notes |
|
Procedure Details:
-
Collateral ventilation negative (confirmed with Chartis® Pulmonary Assessment System)
-
Six Zephyr® Valves placed in left upper lobe (LUL)
-
Total procedure time—25 mins
Pre and Post Imaging:
Pre-procedure
Evidence of hyperinflation with flattening of the diaphragm
Post-procedure
Atelectasis of LUL with elevation of left hemidiaphragm
Pre and Post Lung Function Chart:
| ASSESSMENT | PRE-PROCEDURE | POST-PROCEDURE (3 MONTHS) |
|---|---|---|
| FEV1 (% pred) | 24% | 31% |
| RV (% pred) | 235% | 129% |
| TLC (% pred) | 126% | 95% |
| DLCO (% pred) | 46% | 53% |
| 6MWD | 160 m | 320 m |
| Oxygen Use | 3L/min | 2L/min |
Case was Completed by:
Dr. Jonathan Kurman at Medical College of Wisconsin, Wauwatosa, WI
Patient Outcome:
-
33% decrease in oxygen use
-
100% increase in 6MWD
-
30% increase in FEV1
-
Post-treatment StratX® Lung Report shows 100% Target lobar volume reduction (TLVR) with 1532 mL inspiratory volume
-
Disease symptoms are more controlled
-
Overall improvement in quality of life
-
Able to handle everyday tasks around the house
How the Zephyr Valve Works:
The Zephyr Valve is a one-way valve designed to reduce hyperinflation of the lungs caused by severe emphysema/COPD. In a minimally invasive bronchoscopic procedure, an average of four tiny valves are placed in the airways to block off the diseased parts of the lungs where air gets trapped, causing hyperinflation and severe shortness of breath. The Zephyr Valve reduces lung hyperinflation by allowing trapped air to escape and preventing new air from entering that diseased lobe. This allows the healthier parts of the lung to function better and results in patients being able to breathe more easily and experience less shortness of breath.1
The Zephyr Endobronchial Valve is removable, and thus preserves future therapy options.
If you have a patient to refer, find a treatment center in your area.
Zephyr Valve Patient Benefits and Risks:
Patients treated report significant improvements in lung function, exercise tolerance, and quality of life.1
Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.
Results in other cases may vary.
GLO-EN-1318-v1
Important Safety Information: The Pulmonx Zephyr Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV1 <15% of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events. Caution: Federal law restricts this device to sale by or on the order of a physician.
